Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Seagen Says FDA Grants Priority Review For Supplemental Biologics License Application (sBLA) Of PADCEV (enfortumab vedotin-ejfv) With KEYTRUDA (pembrolizumab) For First-Line Treatment Of Advanced Bladder Cancer

Author: Benzinga Newsdesk | November 30, 2023 06:03pm

Posted In: MRK SGEN